Hydroxychloroquine tied to increased CV risk
17 Dec 2020
byAudrey Abella
While hydroxychloroquine (HCQ) alone seems to have no increased cardiovascular (CV) risk when used in the short-term (up to 30 days) for rheumatoid arthritis (RA), combining it with azithromycin (AZM) led to increased risks of CV mortality, angina, and heart failure (HF). Moreover, long-term use conferred excess CV mortality, a retrospective study suggests.
